Vontobel Holding Ltd. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 75.2% in ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

Canaccord analyst Whitney Ijem raised the firm’s price target on Alnylam (ALNY) to $385 from $384 and keeps a Buy rating on the shares. The ...

Q4 2024 Earnings Call Transcript February 13, 2025 Alnylam Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Morgan Stanley from $275.00 to $284.00 in a research note issued to investors on Friday,Benzinga reports. Morgan ...

Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

Reports Q4 revenue $593.17M, consensus $580.62M. “2024 was another year of impressive execution for Alnylam (ALNY), generating product revenues ...